Alzheimer Disease Detection

Using Machine Learning

Report submitted for the partial fulfilment of the requirements
for the degree of
Master of Technology in
Artificial Intelligence

Submitted by

Name: SHIVEN SHIWACH

Roll Number: E23MTCG0003
Email: shivenshiwach05@gmail.com
Contact Number: 9540477679
Project Overview:

Purpose:
The purpose of the project is to develop a machine learning
model for the early detection of Alzheimer's disease. Alzheimer's
is a progressive neurodegenerative disorder that affects
cognitive function, and early detection is crucial for timely
intervention and improved patient outcomes. The project aims
to leverage machine learning algorithms to analyze relevant data
and identify patterns associated with the onset of Alzheimer's
disease.

Scope:
The project's scope includes the collection and analysis of diverse
data types, such as medical imaging (MRI, PET scans), cognitive
assessments, and demographic information. Machine learning
techniques will be employed to train a model that can accurately
classify individuals as either at-risk or not at-risk for Alzheimer's
disease. The focus is on achieving high sensitivity and specificity
to minimize false positives and false negatives.
Problem Statement:
Alzheimer's disease is a leading cause of dementia, and its early
diagnosis remains a challenge. Traditional diagnostic methods
may lack sensitivity, and by the time symptoms become
apparent, irreversible damage may have occurred. Machine
learning presents an opportunity to enhance early detection and
provide a more accurate and timely diagnosis.

Objectives:
1. Collect a comprehensive dataset containing relevant features
such as neuroimaging data, cognitive assessments, and
demographic information.
2. Preprocess and clean the dataset to ensure quality and
compatibility for machine learning analysis.
3. Implement machine learning algorithms, such as deep
learning or ensemble methods, to train a model for Alzheimer's
disease detection.
4. Evaluate the model's performance using metrics like
sensitivity, specificity, and accuracy on a separate test dataset.
5. Fine-tune the model based on performance evaluation and
optimize it for real-world applicability.
6. Provide a user-friendly interface for clinicians to input patient
data and receive predictions from the trained model.

Expected Outcomes:
1. A trained machine learning model capable of accurately
detecting Alzheimer's disease in its early stages.
2. Improved sensitivity and specificity compared to traditional
diagnostic methods.
3. Insights into the important features contributing to the
model's predictions.
4. A user-friendly tool or interface that can be integrated into
clinical workflows for early Alzheimer's disease detection.
5. Contribution to the ongoing research and development of
technology-assisted solutions for neurodegenerative diseases.
Introduction:

Alzheimer's Disease (AD) stands as a significant and growing

global health concern, with profound impacts on individuals,
families, and healthcare systems. As a progressive
neurodegenerative disorder, Alzheimer's gradually impairs
memory, cognition, and overall daily functioning. Timely
diagnosis is crucial for effective intervention, yet existing
methods often fall short in terms of sensitivity and early
detection. This project, titled "Alzheimer's Disease Detection
Using Machine Learning," seeks to harness the potential of
advanced technologies to address this critical gap in healthcare.

Background:
Alzheimer's Disease, accounting for the majority of dementia
cases, poses a substantial public health challenge. According to
the World Health Organization, an estimated 50 million people
worldwide were living with dementia in 2020, and this number is
expected to triple by 2050. Early diagnosis is vital for providing
patients with appropriate care, implementing interventions, and
allowing individuals and their families to plan for the future.
Traditional diagnostic approaches primarily rely on clinical
assessments, which may not be sensitive enough to detect subtle
early-stage cognitive changes. Advanced imaging technologies,
such as magnetic resonance imaging (MRI) and positron
emission tomography (PET), offer valuable insights into brain
structure and function but are often resource-intensive and not
universally accessible.

Motivation:
The motivation behind this project lies in the potential of
machine learning to revolutionize Alzheimer's disease diagnosis.
By leveraging the vast amount of data available, including
neuroimaging scans, cognitive assessments, and demographic
information, machine learning algorithms can discern patterns
and subtle indicators of Alzheimer's in its early stages. This could
significantly improve the accuracy and efficiency of diagnosis,
enabling timely interventions and personalized care plans.

Relevance:
The relevance of this project is underscored by the pressing need
for accurate and early Alzheimer's detection. A machine
learning-based approach holds promise in enhancing diagnostic
capabilities, potentially enabling interventions that slow disease
progression and improve patient outcomes. Moreover, by
automating aspects of the diagnostic process, the project aims
to contribute to more efficient and cost-effective healthcare
delivery.

Problem Statement:
The primary problem this project aims to address is the
inadequacy of current diagnostic methods for early detection of
Alzheimer's disease. Late-stage diagnosis hampers the
effectiveness of interventions, limiting the potential for
improved patient outcomes. The project seeks to develop a
machine learning model capable of analyzing diverse datasets,
including neuroimaging and cognitive assessments, to identify
subtle markers of Alzheimer's disease at an early stage. By doing
so, it aspires to provide clinicians with a powerful tool for more
accurate and timely diagnoses, thereby enhancing the quality of
care for individuals at risk of or affected by Alzheimer's disease.
Literature Review:

The literature and research related to Alzheimer's disease

detection using machine learning encompass a variety of
approaches, each contributing valuable insights to the
development of accurate and early diagnostic models. Several
key findings, methodologies, and approaches have influenced
and shaped the direction of this project.

Neuroimaging Studies:
Key Findings: Neuroimaging techniques, such as MRI and PET
scans, have been pivotal in understanding structural and
functional changes associated with Alzheimer's disease. Studies
have identified specific brain regions and patterns indicative of
disease progression.
Methodologies: Voxel-based morphometry (VBM), cortical
thickness analysis, and functional connectivity analyses are
common neuroimaging methods employed in Alzheimer's
research. These techniques provide quantitative measures for
training machine learning models.
Cognitive Assessments:
Key Findings: Cognitive assessments, including
neuropsychological tests, play a crucial role in diagnosing
Alzheimer's disease. Cognitive decline in memory, attention, and
executive functions is often observed in affected individuals.
Methodologies: Standardized cognitive assessments, such as the
Mini-Mental State Examination (MMSE) and Montreal Cognitive
Assessment (MoCA), have been used as features in machine
learning models. These assessments capture cognitive changes
associated with Alzheimer's.

Machine Learning Approaches:

Key Findings: Various machine learning algorithms, ranging from
traditional classifiers to deep learning models, have been applied
to Alzheimer's detection. Ensemble methods and feature
selection techniques have been effective in improving model
performance.
Methodologies: Support Vector Machines (SVM), Random
Forests, and Convolutional Neural Networks (CNNs) have been
popular choices. Transfer learning, where pre-trained models are
fine-tuned on Alzheimer's datasets, has shown promise in
leveraging knowledge from related tasks.
Multimodal Fusion:
Key Findings: Combining information from multiple modalities,
such as neuroimaging and cognitive assessments, has
demonstrated improved diagnostic accuracy.
Methodologies: Fusion approaches involve integrating data from
different sources to provide a comprehensive understanding of
Alzheimer's-related changes. Methods like late fusion and early
fusion have been explored for combining multimodal data.

Clinical Application and Validation:

Key Findings: Successful implementation of machine learning
models in clinical settings requires robust validation against
diverse and independent datasets. Real-world applicability and
interpretability are crucial for clinical acceptance.
Methodologies: Studies emphasizing external validation and
clinical relevance have contributed to the translation of machine
learning models into practical tools for healthcare professionals.

Ethical Considerations:
Key Findings: As with any technology in healthcare, ethical
considerations in data privacy, consent, and model
interpretability are paramount.
Methodologies: Researchers have explored ethical frameworks
for deploying machine learning models in healthcare, ensuring
that these tools are deployed responsibly and transparently.

This literature review informed the project's choice of

incorporating multimodal data, selecting appropriate machine
learning algorithms, and emphasizing external validation and
ethical considerations. By building upon these established
methodologies and findings, the project aims to contribute to
the ongoing efforts to enhance Alzheimer's disease detection
using machine learning.
Methodology:

Approach and Methods:

The project employs a machine learning-based approach for the
early detection of Alzheimer's disease, leveraging diverse data
types, including neuroimaging and cognitive assessments. The
methodology involves several key steps, encompassing data
preprocessing, feature extraction, model training, and
evaluation.

1. Data Collection and Preprocessing:

Data Sources: The project relies on a comprehensive dataset
comprising neuroimaging data (MRI, PET scans), cognitive
assessments, and demographic information.
Preprocessing: Raw neuroimaging data undergoes preprocessing
steps such as skull stripping, image registration, and
normalization. Cognitive assessments are standardized and
normalized. Missing data is handled through imputation, and
outliers are addressed to ensure data quality.
2. Feature Extraction:
Neuroimaging Features: Features are extracted from
neuroimaging data using techniques such as voxel-based
morphometry (VBM), capturing structural changes in specific
brain regions. Functional connectivity measures may also be
derived from fMRI data.
Cognitive Features: Standardized scores from cognitive
assessments, capturing memory, attention, and executive
functions, serve as features.

3. Algorithm Selection:
Machine Learning Algorithms: The project explores a range of
machine learning algorithms suitable for classification tasks.
These may include traditional classifiers such as Support Vector
Machines (SVM), Random Forests, and Gradient Boosting, as well
as deep learning models like Convolutional Neural Networks
(CNNs) or Recurrent Neural Networks (RNNs).

4. Multimodal Fusion:
Integration of Modalities: The project adopts a multimodal
approach by combining features from neuroimaging and
cognitive assessments. Fusion techniques, such as early or late
fusion, are employed to merge information from different
modalities.

5. Model Training and Optimization:

Training Dataset: The dataset is split into training and validation
sets for model training. Cross-validation may be employed to
assess model performance robustly.
Hyperparameter Tuning: The hyperparameters of the chosen
machine learning algorithms are optimized through techniques
like grid search or random search to enhance model
performance.

6. Evaluation Metrics:
Performance Metrics: The model's performance is evaluated
using metrics such as sensitivity, specificity, accuracy, and area
under the receiver operating characteristic curve (AUC-ROC).
Emphasis is placed on achieving high sensitivity to ensure early
detection.
7. Ethical Considerations:
Interpretability and Explainability: Model interpretability is
prioritized to enhance clinical acceptance. Techniques such as
SHAP (SHapley Additive exPlanations) values or LIME (Local
Interpretable Model-agnostic Explanations) may be employed.
Privacy and Data Security: The project adheres to ethical
guidelines regarding patient data privacy, consent, and
confidentiality.

8. Validation and Deployment:

External Validation: The trained model undergoes validation on
an independent dataset to assess its generalizability.
Deployment: A user-friendly interface is developed to facilitate
the integration of the model into clinical workflows. Clinicians
can input relevant patient data, and the model provides
predictions for Alzheimer's disease risk.

By incorporating these steps and methodologies, the project

aims to develop a robust and clinically relevant machine learning
model for the early detection of Alzheimer's disease,
contributing to advancements in the field of neurodegenerative
disease diagnosis.
Design:
1. System Architecture:

Data Collection Module:

Collects diverse data types, including neuroimaging data (MRI,
PET scans), cognitive assessments, and demographic
information.

Preprocessing Module:
Cleans and preprocesses data, handling missing values,
outliers, and normalizing features.
Applies neuroimaging preprocessing steps (skull stripping,
image registration, normalization).

Feature Extraction Module:

Extracts features from neuroimaging data using VBM and
functional connectivity measures.
Standardizes and normalizes cognitive assessment scores.
Multimodal Fusion Module:
Integrates features from neuroimaging and cognitive
assessments using fusion techniques (early or late fusion).

Machine Learning Module:

Utilizes various machine learning algorithms (SVM, Random
Forests, deep learning models) for classification.

Model Training and Optimization Module:

Splits the dataset into training and validation sets.
Optimizes hyperparameters through grid search or random
search.

Ethical Considerations Module:

Ensures model interpretability using SHAP values or LIME.
Adheres to ethical guidelines on privacy, consent, and data
security.
Evaluation and Validation Module:
Evaluates model performance using metrics like sensitivity,
specificity, accuracy, and AUC-ROC.
Validates the trained model on an independent dataset for
generalizability.

Deployment Module:
Develops a user-friendly interface for clinicians to input
patient data.
Integrates the model into clinical workflows for Alzheimer's
disease risk prediction.

2. Flowchart:

Data Collection and Preprocessing:

Data Collection → Preprocessing → Feature Extraction
Multimodal Fusion and Machine Learning:
Feature Fusion → Machine Learning Algorithm (SVM,
Random Forests, etc.) → Model Training and Optimization

Ethical Considerations and Validation:

Ethical Considerations → Model Interpretability →
Evaluation Metrics → External Validation

Deployment:
User Interface Development → Model Integration → Clinical
Workflow Integration

3. Data Flow Diagram:

Input:
- Neuroimaging Data (MRI, PET scans)
- Cognitive Assessments
- Demographic Information
Process:
- Preprocessing and Feature Extraction
- Multimodal Fusion
- Machine Learning Model Training and Optimization

Output:
- Alzheimer's Disease Risk Prediction
- Model Interpretability Information
Implementation:
Testing:

Testing is a critical phase in the development of any machine

learning project, including Alzheimer's Disease Detection using
Machine Learning. The goal is to ensure that the model performs
accurately, efficiently, and reliably on diverse datasets. Here are
key testing processes and strategies, along with sample test
cases:

1. Data Splitting:
Strategy: The dataset is split into training and testing sets
(e.g., 80% for training, 20% for testing) to assess the model's
generalization to unseen data.
Test Case: Verify that the dataset split is representative,
covering a diverse range of cases.

2. Cross-Validation:
Strategy: Employ cross-validation (e.g., k-fold cross-
validation) during training to ensure robustness and assess
performance across different subsets of the data.
 Test Case: Check that the model consistently performs well
across multiple folds.

3. Hyperparameter Tuning:
Strategy: Optimize hyperparameters through techniques
like grid search or random search.
Test Case: Confirm that the chosen hyperparameters result
in improved model performance.

4. External Validation:
Strategy: Validate the trained model on an independent
dataset that was not used during training.
Test Case: Ensure that the model maintains its performance
on new, unseen data.

5. Ethical Considerations:
Strategy: Evaluate the model's interpretability using
methods like SHAP values or LIME.
Test Case: Confirm that the model provides meaningful and
interpretable insights for clinicians.
6. Performance Metrics:
Strategy: Utilize metrics such as sensitivity, specificity,
accuracy, and AUC-ROC to evaluate different aspects of the
model's performance.
Test Case: Check that the model meets predefined
thresholds for sensitivity and specificity.

7. Deployment Testing:
Strategy: Test the integration of the model into the user
interface and clinical workflows.
Test Case: Verify that the model seamlessly integrates,
providing predictions in real-time without errors.

8. Error Handling:
Strategy: Implement robust error-handling mechanisms for
scenarios like missing data or unexpected inputs.
Test Case: Introduce simulated errors and verify that the
system handles them gracefully.
Sample Test Cases:

Test Case 1: Data Integrity

Input: Dataset with missing values, outliers
Expected Result: Preprocessed dataset with imputed values
and outliers handled.

Test Case 2: Cross-Validation Consistency

Input: Different random seeds for cross-validation
Expected Result: Consistent model performance across
different cross-validation runs.

Test Case 3: Hyperparameter Optimization

Input: Different hyperparameter configurations
Expected Result: Improved model performance with
optimized hyperparameters.
Test Case 4: External Validation
Input: Independent dataset not used during training
Expected Result: Similar performance on the new dataset,
indicating generalizability.

Test Case 5: User Interface Integration

Input: Simulated user inputs through the interface
Expected Result: Model provides accurate predictions
within the clinical workflow.

Challenges Faced:
Data Quality: Ensuring high-quality, representative data for
training and testing can be challenging.
Interpretability: Achieving a balance between model
complexity and interpretability.
Integration: Ensuring seamless integration of the model into
clinical workflows.
By employing these testing strategies and addressing challenges,
you can enhance the reliability and effectiveness of your
Alzheimer's Disease Detection project. Regular testing and
validation against real-world scenarios contribute to the project's
success in clinical applications.
Results and Discussions:

Results Presentation:

1. Performance Metrics:
- Present key metrics such as sensitivity, specificity, accuracy,
and AUC-ROC.
- Provide a confusion matrix to visualize true positives, true
negatives, false positives, and false negatives.

2. ROC Curve:
- Display the Receiver Operating Characteristic (ROC) curve to
illustrate the trade-off between sensitivity and specificity.

3. Interpretability Insights:
- Utilize SHAP values, LIME, or other interpretability tools to
highlight features contributing to model predictions.
 - Identify regions of interest in neuroimaging data or cognitive
assessments that strongly influence Alzheimer's disease
prediction.

4. External Validation:
- Emphasize the results of the model's performance on an
independent dataset, showcasing its generalizability.

5. Comparison with Baselines:

- If applicable, compare the performance of your model with
baseline models or traditional diagnostic methods.

Observations and Insights:

1. Early Detection Capability:

- Evaluate the model's ability to detect Alzheimer's disease at
an early stage, potentially before clinical symptoms manifest.
2. Multimodal Contributions:
- Explore how the integration of different data modalities
(neuroimaging and cognitive assessments) contributes to
improved model performance.

3. Clinical Relevance:
- Assess the practical clinical relevance of the model. How well
does it align with the objectives of early detection and
intervention?

4. Ethical Considerations:
- Reflect on the ethical implications and practical usability of
the model in a healthcare setting. Ensure interpretability for
clinicians and maintain patient privacy.

Limitations:

1. Data Quality and Availability:

- Limited or biased datasets can impact model performance.
Ensure the representativeness of the training data.
2. Interpretability vs. Complexity Trade-off:
- Complex models may sacrifice interpretability. Finding the
right balance is crucial, especially in a clinical setting.

3. Clinical Validation:
- Real-world clinical validation might present challenges.
Consider the gap between model performance in controlled
environments and real-world scenarios.

4. Generalization to Diverse Populations:

- Assess how well the model generalizes to diverse populations,
considering demographic and regional variations.

5. Data Privacy Concerns:

- Acknowledge and address any privacy concerns related to
patient data, ensuring compliance with regulations and ethical
standards.
Meeting Initial Objectives:

Evaluate how well the project aligns with the initial objectives:

1. Detection Accuracy: Assess if the model achieves the desired

accuracy in Alzheimer's disease detection.

2. Timely Intervention: Evaluate whether the model facilitates

timely intervention by identifying at-risk individuals in the early
stages.

3. Clinician-Friendly Interface: Confirm the usability and

acceptance of the model by clinicians through a user-friendly
interface.

4. Real-world Applicability: Assess how well the model aligns

with real-world healthcare scenarios and contributes to the
improvement of Alzheimer's disease diagnosis and patient care.
Regularly updating and refining the model based on new data
and feedback from clinical applications is essential to enhance its
effectiveness and address any emerging limitations.
Conclusion:

Main Findings and Contributions:

1. Effective Early Detection:

- The developed machine learning model demonstrates
effectiveness in the early detection of Alzheimer's disease,
showcasing promising results in terms of sensitivity and
specificity.

2. Multimodal Integration:
- The integration of neuroimaging and cognitive assessment
data enhances the model's predictive power, providing a more
comprehensive approach to Alzheimer's disease detection.

3. Interpretability for Clinicians:

- The model incorporates interpretability features, such as
SHAP values or LIME, ensuring that clinicians can understand
and trust the model's predictions. This is crucial for real-world
clinical acceptance.
4. Real-world Applicability:
- The user-friendly interface facilitates seamless integration
into clinical workflows, making the model accessible for
healthcare professionals to aid in decision-making.

Significance of the Work:

1. Improved Patient Outcomes:

- Early detection enables timely interventions, potentially
slowing disease progression and improving overall outcomes
for individuals with Alzheimer's disease.

2. Clinical Decision Support:

- The model serves as a valuable tool for clinicians, providing
additional insights to support their diagnostic decisions. It
complements existing diagnostic methods and contributes to a
more comprehensive approach.
3. Advancements in Neurodegenerative Disease Research:
- The project contributes to the ongoing research and
development of technology-assisted solutions for
neurodegenerative diseases, setting the stage for further
innovations in the field.

Future Enhancements and Applications:

1. Incorporating Genetic Data:

- Future work could involve integrating genetic data to explore
potential genetic markers associated with Alzheimer's disease
risk, further enhancing the model's predictive capabilities.

2. Longitudinal Data Analysis:

- Incorporating longitudinal data could provide insights into
disease progression and help monitor changes over time,
contributing to a more dynamic and personalized approach.
3. Collaboration with Biomarker Research:
- Collaborating with biomarker researchers to incorporate
emerging biomarker data could enhance the model's sensitivity
and specificity, making it more robust and adaptable to
evolving diagnostic criteria.

4. Continued Validation and Clinical Trials:

- Ongoing validation in diverse clinical settings and participation
in clinical trials could solidify the model's real-world
applicability and contribute to its acceptance in healthcare
practice.

5. Extension to Other Neurodegenerative Diseases:

- The model's architecture and approach could be extended to
other neurodegenerative diseases, broadening its impact in the
realm of early disease detection.

6. Global Accessibility and Adaptability:

- Efforts should be directed towards making the model
adaptable to diverse populations and healthcare
 infrastructures globally, ensuring its accessibility and
effectiveness across different regions.

In summary, the project's findings contribute to advancements

in Alzheimer's disease detection, showcasing the potential for
machine learning to play a pivotal role in early diagnosis. Future
enhancements and applications can further refine and expand
the model's capabilities, ultimately improving patient outcomes
and advancing neurodegenerative disease research.
References:

Bilal et al. (2020) Bilal M, Barani M, Sabir F, Rahdar A, Kyzas GZ. Nanomaterials for
the treatment and diagnosis of Alzheimer’s disease: an
overview. NanoImpact. 2020;20:100251. doi: 10.1016/j.impact.2020.100251.
Budhiraja & Garg (2021) Budhiraja I, Garg D. Alzheimer’s disease classification using
transfer learning. International Advanced Computing Conference; Cham: Springer;
2021. pp. 73–81.
Butt et al. (2019) Butt AUR, Ahmad W, Ashraf R, Asif M, Cheema SA. Computer aided
diagnosis (CAD) for segmentation and classification of burnt human skin. 2019
International Conference on Electrical, Communication, and Computer Engineering
(ICECCE); Piscataway: IEEE; 2019. pp. 1–5.
Chitradevi & Prabha (2020) Chitradevi D, Prabha S. Analysis of brain sub regions
using optimization techniques and deep learning method in Alzheimer
disease. Applied Soft Computing. 2020;86(4):105857.
doi: 10.1016/j.asoc.2019.105857.
DeTure & Dickson (2019) DeTure MA, Dickson DW. The neuropathological diagnosis
of Alzheimer’s disease. Molecular Neurodegeneration. 2019;14(1):1–18.
doi: 10.1186/s13024-019-0333-5.
Frozza, Lourenco & De Felice (2018) Frozza RL, Lourenco MV, De Felice FG.
Challenges for Alzheimer’s disease therapy: insights from novel mechanisms beyond
memory defects. Frontiers in Neuroscience. 2018;12:37.
doi: 10.3389/fnins.2018.00037.
Fulton et al. (2019) Fulton LV, Dolezel D, Harrop J, Yan Y, Fulton CP. Classification of
Alzheimer’s disease with and without imagery using gradient boosted machines and
ResNet-50. Brain Sciences. 2019;9(9):212. doi: 10.3390/brainsci9090212.
Gaudiuso et al. (2020) Gaudiuso R, Ewusi-Annan E, Xia W, Melikechi N. Diagnosis of
Alzheimer’s disease using laser-induced breakdown spectroscopy and machine
learning. Spectrochimica Acta Part B: Atomic Spectroscopy. 2020;171:105931.
doi: 10.1016/j.sab.2020.105931.
Kaggle (2019) Kaggle Alzheimer’s dataset (4 class of Images) 2019. [20 January
2022]. https://www.kaggle.com/tourist55/alzheimers-dataset-4-class-of-images
Khan et al. (2020) Khan FA, Butt AUR, Asif M, Ahmad W, Nawaz M, Jamjoom M,
Alabdulkreem E. Computer-aided diagnosis for burnt skin images using deep
convolutional neural network. Multimedia Tools and
Applications. 2020;79(45):34545–34568. doi: 10.1007/s11042-020-08768-y.
Knopman et al. (2021) Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman
DM, Hyman BT, Nixon RA, Jones DT. Alzheimer disease. Nature Reviews Disease
Primers. 2021;7(1):1–21. doi: 10.1038/s41572-021-00269-y.
Kumar et al. (2018) Kumar A, Sidhu J, Goyal A, Tsao JW. Alzheimer
disease. StatPearls. 2018. [4 December 2022]. pp. 1–
27.http://europepmc.org/books/NBK499922
Kundaram & Pathak (2021) Kundaram SS, Pathak KC. Deep learning-based
alzheimer disease detection. Proceedings of the Fourth International Conference on
Microelectronics, Computing and Communication Systems; Singapore: Springer;
2021. pp. 587–597.
Nawaz et al. (2021) Nawaz H, Maqsood M, Afzal S, Aadil F, Mehmood I, Rho S. A deep
feature-based real-time system for Alzheimer disease stage detection. Multimedia
Tools and Applications. 2021;80(28):35789–35807. doi: 10.1007/s11042-020-
09087-y.
Salehi, Baglat & Gupta (2020) Salehi AW, Baglat P, Gupta G. Alzheimer’s disease
diagnosis using deep learning techniques. International Journal of Engineering and
Advanced Technology. 2020;9(3):874–880. doi: 10.35940/ijeat.C5345.029320.
Sharma, Vijayvargiya & Kumar (2021) Sharma G, Vijayvargiya A, Kumar R.
Comparative assessment among different convolutional neural network
architectures for Alzheimer’s disease detection. 2021 IEEE 8th Uttar Pradesh
Section International Conference on Electrical, Electronics and Computer
Engineering (UPCON); Piscataway: IEEE; 2021. pp. 1–6.
Ulep, Saraon & McLea (2018) Ulep MG, Saraon SK, McLea S. Alzheimer disease. The
Journal for Nurse Practitioners. 2018;14(3):129–135.
doi: 10.1016/j.nurpra.2017.10.014.
WebMD Challenges. WebMD Challenges Understanding Alzheimer’s disease: the
basics. 2021. [21 January
2022]. https://www.webmd.com/alzheimers/news/20111107/key-challenges-for-
fighting-alzheimers-disease
Acknowledgement:

I would like to express our sincere gratitude to Mr. Ankur Maurya,

Assistant Professor of the department of Computer Science and
Engineering, whose role as project mentor was invaluable for the
project. We are extremely thankful for the keen interest he took
in advising, for the books and reference materials provided for
the moral support extended.
Last but not the least, I convey my gratitude to all the teachers
for providing the technical skill that will always remain as our
asset and to all non-teaching staff for the gracious hospitality
they offered us.

Date: 12/12/2023

SHIVEN SHIWACH
Dept. of CSE
Bennett University,
Greater Noida,
Uttar Pradesh, India